OS Therapies (OSTX) Accounts Payables (2023 - 2026)
OS Therapies' (OSTX) quarterly Accounts Payables came in at $15.2 million in Q1 2026, up 842.46% YoY from $1.6 million in Q1 2025, and up 34.2% on a QoQ basis from $11.4 million in Q4 2025.
OS Therapies (OSTX) Accounts Payables (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Accounts Payables data on file, last reported at $15.2 million in Q1 2026.
- Quarterly Accounts Payables rose 842.46% year-over-year to $15.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.2 million (up 842.46% YoY) and the FY2025 annual result came in at $11.4 million, up 582.97% from the prior year.
- Accounts Payables grew to $15.2 million in Q1 2026, from $11.4 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $15.2 million in Q1 2026 to a low of $400000.0 in Q2 2024.
- A 4-year average of $4.1 million and a median of $2.2 million in 2024 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2025 — Accounts Payables slumped 77.43% — and 2026, when it soared 842.46%.
- Tracing OSTX's Accounts Payables over 4 years: stood at $2.7 million in 2023, then plunged by 38.79% to $1.7 million in 2024, then jumped by 582.97% to $11.4 million in 2025, then soared by 34.2% to $15.2 million in 2026.
- The last three Accounts Payables figures came in at $15.2 million (Q1 2026), $11.4 million (Q4 2025), and $400000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 35.57 Mn |
| 10 | OS Therapies | 19.48 Mn | 19.48 Mn | - | 20.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.23 Mn |
| Dec 31, 2025 | 11.35 Mn |
| Sep 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 2.70 Mn |
| Mar 31, 2025 | 1.62 Mn |
| Dec 31, 2024 | 1.66 Mn |
| Sep 30, 2024 | 1.77 Mn |
| Jun 30, 2024 | 400,000.00 |
| Mar 31, 2024 | 2.80 Mn |
| Dec 31, 2023 | 2.72 Mn |